Convertible note offering removes restrictive secured debt and extends runway into 2028, supporting commercial launch. However, the massive debt load (~$701M) and potential dilution from conversion at ~$124.53/share cap upside. Monitor FDA PDUFA on July 17, approval could de-risk the conversion premium. Preferred shares would benefit from the de-levering to unsecured debt.
CELC drugs
CELC drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $88.28entry
- T+1 · 5mo ago −0.96%α −1.19% · $87.43
- T+5 · 5mo ago +0.31%α −0.26% · $88.55
- T+20 · 4mo ago +23.00%α +21.13% · $108.58
- T+60 · 3mo ago +0.88%α −3.12% · $89.06
Price Chart
How similar events traded
Executive Summary
Celcuity is issuing $500M of 0.250% convertible senior notes due 2032 (plus $75M over-allotment). Net proceeds of ~$484.3M will fully repay the $137.9M secured term loan facility and fund working capital, commercial launch, and pipeline expansion through 2028. The de-levering to zero secured debt is a significant credit-positive event, but the large debt raise (~$201M prior converts + $500M new, totaling ~$701M) adds substantial leverage and potential dilution if converted.
Key Facts
- $500M aggregate principal of 0.250% convertible senior notes due 2032
- $75M over-allotment option, total $575M if fully exercised
- Initial conversion price ~$124.53/share, ~40% premium to $88.95 stock price on June 3
- Net proceeds ~$484.3M (or ~$557M with over-allotment)
- Proceeds to fully repay $137.9M secured term loan, eliminating all secured debt
- Post-offering, total long-term debt rises from $339.1M to $701.3M
- Maturity August 1, 2032; interest 0.250% paid semi-annually
- Not redeemable before August 6, 2029; convertible upon stock price conditions or certain corporate events
- Mandatory contingent conversion triggers if stock exceeds 130% of conversion price for 20 of 30 trading days
- FDA PDUFA date for gedatolisib NDA in PIK3CA WT breast cancer is July 17, 2026
- Positive Phase 3 VIKTORIA-1 MT data announced June 2, 2026, sNDA planned Q3 2026
Financial Impact
De-levering: $137.9M secured debt eliminated; new debt: $500M-$575M. Net cash infusion ~$484M after expenses. Total debt rises from $339M to $701M. Prepayment fee of ~$2.6M incurred.
Risk Factors
- ~$701M total debt after offering significantly increases financial leverage
- Potential dilution from conversion: ~4M shares per $500M at $124.53, plus ~4M from existing 2031 converts at $51.30
- Unsecured notes rank equal with existing 2031 converts but effectively junior to any future secured debt
- No public trading market expected for the notes; illiquidity premium
- If stock does not appreciate above $124.53, convert notes remain out of the money, overhang without upside
- PIK element on prior term loan was expensive (~7.75%+2.85%); replacement with 0.25% coupon is cheaper but riskier (convertible)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-027395 |
| Exhibit: ex107.htm | 0001493152-26-027395 |
| Document: 0001493152-26-027395-index-headers.html | 0001493152-26-027395 |
| Document: 0001493152-26-027395-index.html | 0001493152-26-027395 |
| Document: 0001493152-26-027395.txt | 0001493152-26-027395 |
Track record
26 reports on CELC
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers